Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders

Seventy-seven studies on serotonergic psychedelics showed only low-level evidence for their safety and efficacy in treating mental and substance use disorders.

• The review included 43 studies on LSD, 24 on ayahuasca, and 5 each on DMT, ibogaine, and mescaline.
• Reported benefits of these substances included improved mood and anxiety, better insight, reduced substance use, improved relationships, and decreased vegetative symptoms.
• Adverse effects were commonly psychological, neurological, physical, and gastrointestinal.
• Serious adverse events, such as homicide and suicide, were noted in studies involving LSD.
• The overall findings indicate a lack of robust evidence for the therapeutic use of these psychedelics outside of psilocybin.

AI simplified